In contrast, studies in the MMTV-PyVT mouse model of breast cancer have suggested that tumor-suppressive effects of the TGF-β pathway may persist even in late-stage metastatic disease [26-28]. This evidence concerns the gene TGFB1 and breast carcinoma.